Type
Offshoring/Delocalisation
Country
Netherlands
Region
Zuid-Nederland; Noord-Brabant; Noordoost-Noord-Brabant
Location of affected unit(s)
Oss
Sector
Manufacturing
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21.2 - Manufacture Of Pharmaceutical Preparations
New offshoring locations
Not Available

495 jobs
Number of planned job losses
Job loss
Announcement Date
1 October 2024
Employment effect (start)
1 October 2024
Foreseen end date

Description

The Dutch pharmaceutical company MSD is restructuring. It is announced that 200 jobs will be cut and that 295 jobs will be relocated following MSD’s sale of its factory in Oss.

The sale of the factory, which produced immunotherapy, is a result of MSD’s plan to focus on production locations outside the Netherlands. According to the company, these production locations together have the sufficient capacity to fulfil the demand for MSD’s immunotherapy.

As of October 2024, it is unknown how the restructuring will proceed or when it will end. It is also unknown which unit is affected the most by the job reduction. However, it is known that 120 office jobs will remain in Oss.


Sources

Citation

Eurofound (2024), MSD, Offshoring/Delocalisation in Netherlands, factsheet number 201688, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/201688.